Sight Sciences (SGHT) Expected to Announce Quarterly Earnings on Thursday

Sight Sciences (NASDAQ:SGHT - Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect Sight Sciences to post earnings of ($0.29) per share and revenue of $16.51 million for the quarter. Sight Sciences has set its FY 2025 guidance at EPS.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The firm had revenue of $19.07 million during the quarter, compared to analyst estimates of $18.98 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. During the same period in the prior year, the firm earned ($0.22) earnings per share. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Trading Up 1.9 %

Shares of NASDAQ SGHT traded up $0.06 during midday trading on Tuesday, hitting $3.15. The stock had a trading volume of 168,265 shares, compared to its average volume of 209,415. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. Sight Sciences has a 1-year low of $2.03 and a 1-year high of $8.45. The company has a fifty day moving average price of $2.62 and a 200 day moving average price of $3.39. The company has a market capitalization of $161.70 million, a price-to-earnings ratio of -3.09 and a beta of 2.46.

Analysts Set New Price Targets

SGHT has been the topic of several research analyst reports. UBS Group reduced their price objective on Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research note on Monday, January 27th. Piper Sandler decreased their price target on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating for the company in a report on Thursday, March 6th. Lake Street Capital lowered their price target on Sight Sciences from $3.00 to $2.50 and set a "hold" rating on the stock in a research report on Thursday, March 6th. Citigroup reduced their target price on shares of Sight Sciences from $4.60 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research note on Wednesday, April 9th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $3.83.

Insider Activity

In other news, CEO Paul Badawi sold 24,174 shares of the company's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total transaction of $55,600.20. Following the completion of the sale, the chief executive officer now directly owns 6,010,580 shares in the company, valued at approximately $13,824,334. This represents a 0.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Manohar K. Raheja acquired 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were acquired at an average price of $2.73 per share, with a total value of $27,300.00. Following the completion of the transaction, the executive vice president now owns 145,000 shares in the company, valued at $395,850. The trade was a 7.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 35,196 shares of company stock worth $81,001 in the last 90 days. Corporate insiders own 28.90% of the company's stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.